GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (NSE:GLENMARK) » Definitions » 3-Year Dividend Growth Rate

Glenmark Pharmaceuticals (NSE:GLENMARK) 3-Year Dividend Growth Rate : 7.70% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals 3-Year Dividend Growth Rate?

Glenmark Pharmaceuticals's Dividends per Share for the three months ended in Dec. 2023 was ₹0.00.

The historical rank and industry rank for Glenmark Pharmaceuticals's 3-Year Dividend Growth Rate or its related term are showing as below:

NSE:GLENMARK' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -32.5   Med: 7.7   Max: 71
Current: 7.7

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Glenmark Pharmaceuticals was 71.00% per year. The lowest was -32.50% per year. And the median was 7.70% per year.

NSE:GLENMARK's 3-Year Dividend Growth Rate is ranked worse than
53.11% of 322 companies
in the Drug Manufacturers industry
Industry Median: 9.55 vs NSE:GLENMARK: 7.70

During the past 3 years, the average Dividends Per Share Growth Rate was 7.70% per year. During the past 5 years, the average Dividends Per Share Growth Rate was 5.90% per year. During the past 10 years, the average Dividends Per Share Growth Rate was 2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Glenmark Pharmaceuticals's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, Glenmark Pharmaceuticals's Dividend Yield % is 0.24%.

Warning Sign:

Glenmark Pharmaceuticals Ltd stock dividend yield is close to 5-year low.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Glenmark Pharmaceuticals's 3-Year Dividend Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Pharmaceuticals's 3-Year Dividend Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's 3-Year Dividend Growth Rate falls into.



Glenmark Pharmaceuticals 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Glenmark Pharmaceuticals  (NSE:GLENMARK) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Glenmark Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2023 )/ EPS without NRI (Q: Dec. 2023 )
=0/ -14.316
=N/A

During the past 13 years, the highest Dividend Payout Ratio of Glenmark Pharmaceuticals was 0.27. The lowest was 0.06. And the median was 0.08.

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Glenmark Pharmaceuticals Recent Full-Year* Dividend History

Amount Ex-date Record Date Pay Date Type Frequency Forex Rate
INR 2.5000002023-09-182023-09-192023-10-03Cash DividendannuallyINR:INR 1.000000

* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.

Glenmark Pharmaceuticals's Dividend Yield (%) for Today is calculated as

Dividend Yield %=Most Recent Full Year Dividend/Current Share Price
=2.5/1053.30
=0.24 %

Current Share Price is ₹1053.30.
Glenmark Pharmaceuticals's Dividends per Share for the trailing twelve months (TTM) ended in Today is ₹2.5.

During the past 13 years, the highest Dividend Yield of Glenmark Pharmaceuticals was 1.00%. The lowest was 0.16%. And the median was 0.35%.

Warning Sign:

Glenmark Pharmaceuticals Ltd stock dividend yield is close to 5-year low.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glenmark Pharmaceuticals 3-Year Dividend Growth Rate Related Terms>


Glenmark Pharmaceuticals (NSE:GLENMARK) Business Description

Traded in Other Exchanges
Address
Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals (NSE:GLENMARK) Headlines

No Headlines